Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer
FDA approval pairs Guardant360 CDx with AstraZeneca’s ETCAMAH, a landmark regulatory catalyst in advanced breast cancer.
What changed
FDA approval pairs Guardant360 CDx with AstraZeneca’s ETCAMAH, a landmark regulatory catalyst in advanced breast cancer.
Why it matters
FDA approval pairs Guardant360 CDx with AstraZeneca’s ETCAMAH, a landmark regulatory catalyst in advanced breast cancer. — impact context not separately stored; see What changed.
← Dashboard
Sep 04, 2026 10:46 PM ET